QURE
uniQure N.V.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jun 11 to Jul 2 ▼ 9 days of insider sells: $16.5M by 11 insiders, avg $43.76
- Jun 17 ▲ uniQure announced that the FDA has agreed the 3-year analysis from t…
- Jun 24 uniQure priced a $225M underwritten public offering of 4,945,055 ord…
- Jun 25 Activist stake: uniQure Announces Closing of Upsized Public Offering and F…
- Jul 29 ▲ uniQure reported Q2 2026 results with a net loss of $1.22 per share,…
- Sep 2 ▲ uniQure announced submission of a Biologics License Application (BLA…
- Oct 5 ▼ Barclays downgrades
- Nov 2 ▲ uniQure announced that the FDA has accepted for review its Biologics…
- Nov 2 ▲ uniQure announced FDA acceptance and Priority Review of its BLA for…
- Nov 4 ▲ The headline event is the FDA granting Priority Review of the BLA fo…
- Nov 4 The headline event is the FDA's acceptance of the BLA for AMT-130 in…
- Nov 6 ▼ 1 insider sell $192.9K at $21.25
Signal stack
Where each data set points today.
- InsidersBEARISH
11 insiders sold $16.7M.
- InstitutionsBULLISH
Q3 2026: 22 added (1 new), 12 trimmed or exited.
- AnalystsBULLISH
17 of 20 rate it Buy or better.
- Short sellersSTEADY
Short interest −2.5% to 8.51M shares. 6.4 days to cover, ≈12.1% of shares.
- TrendRANGE
19% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 2.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MORGAN STANLEY | ADD | $46.7M |
| Aberdeen Group plc | TRIM | $46.3M |
| JANE STREET GROUP, LLC | TRIM | $23.4M |
| FMR LLC | TRIM | $21.8M |
| MARSHALL WACE, LLP | ADD | $13.9M |
| CITIGROUP INC | DOUBLED | $13.4M |
| HRT FINANCIAL LP | DOUBLED | $13.0M |
| UBS Group AG | TRIM | $8.0M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
20 analysts| Date | Firm | Rating |
|---|---|---|
| Oct 5, 2026 | Barclays DOWNGRADE | Equal-Weight |
| Oct 2, 2026 | RBC Capital MAINTAIN | Outperform |
| Sep 30, 2026 | Goldman Sachs MAINTAIN | Neutral |
| Jul 30, 2026 | Wells Fargo MAINTAIN | Overweight |
| Jul 30, 2026 | Wolfe Research UPGRADE | Outperform |
| Jul 30, 2026 | Barclays MAINTAIN | Overweight |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Meek David D. Director Nov 6, 2026 | SELL | $192.9K |
Abi-Saab Walid Chief Medical Officer Oct 30, 2026 | AWARD | 18,750 sh |
Kapusta Matthew C CEO, Managing Director Jul 2, 2026 | SELL | $194.5K |
Kapusta Matthew C CEO, Managing Director Jul 2, 2026 | SELL | $408.8K |
Kapusta Matthew C CEO, Managing Director Jul 2, 2026 | SELL | $348.8K |
Kapusta Matthew C CEO, Managing Director Jul 2, 2026 | EXERCISE | $408.8K |
Kaye Jack Director Jun 30, 2026 | SELL | $190.9K |
Abi-Saab Walid Chief Medical Officer Jun 30, 2026 | SELL | $464.6K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
35 filings · 3 press releases · 5 bullish · 5 bearish · 2 mixed · 23 neutral- NEUTRAL 144Nov 6, 2026
Director David D. Meek filed a Form 144 notice of intent to sell 9,080 ordinary shares of uniQure…
The filing is a routine pre-planned sale under a 10b5-1 program; no immediate read-through for the stock. Monitor the company's next earnings release and pipeline updates for fundamental catalysts.
- BULLISH 8-KNov 4, 2026
The headline event is the FDA granting Priority Review of the BLA for AMT-130 (ifezuntirgene…
The PDUFA date of May 1, 2027 is the key catalyst. Watch for confirmatory study enrollment updates and any FDA advisory committee meeting announcement. The UK MAA validation adds a second regulatory…
- NEUTRAL PRESS-RELEASENov 4, 2026
The headline event is the FDA's acceptance of the BLA for AMT-130 in Huntington's disease under…
The FDA Priority Review for AMT-130 is the key catalyst; watch for the PDUFA decision on May 1, 2027 and any updates on the confirmatory study enrollment. The EPS miss is modest and typical for a…
- BULLISH 8-KNov 2, 2026
uniQure announced that the FDA has accepted for review its Biologics License Application (BLA) for…
The PDUFA date of May 1, 2027 sets a clear catalyst; watch for the Advisory Committee meeting date and outcome, which will be a key de-risking event. The confirmatory trial initiation by year-end…
All QURE filing & press-release reports (38)
- 144 reportNov 6, 2026
- 8-K reportNov 4, 2026
- PRESS-RELEASE reportNov 4, 2026
- 8-K reportNov 2, 2026
- PRESS-RELEASE reportNov 2, 2026
- SC 13G/A reportOct 16, 2026
- 8-K reportSep 2, 2026
- 8-K reportJul 29, 2026
- CLUSTER reportJul 7, 2026
- CLUSTER reportJul 2, 2026
- CLUSTER reportJul 2, 2026
- 144 reportJul 2, 2026
- 144 reportJun 30, 2026
- 144 reportJun 25, 2026
- 144 reportJun 24, 2026
- 424B5 reportJun 24, 2026
- PRESS-RELEASE reportJun 23, 2026
- 144 reportJun 17, 2026
- CLUSTER reportJun 17, 2026
- 144 reportJun 17, 2026
- 8-K reportJun 17, 2026
- CLUSTER reportJun 12, 2026
- CLUSTER reportJun 12, 2026
- CLUSTER reportJun 12, 2026
- CLUSTER reportJun 12, 2026
- 144 reportJun 11, 2026
- 144 reportJun 11, 2026
- 144 reportJun 11, 2026
- 144 reportJun 3, 2026
- PRESS-RELEASE reportMay 5, 2026
- 8-K reportMay 5, 2026
- DEFA14A reportApr 27, 2026
- CLUSTER reportMar 2, 2026
- CLUSTER reportMar 2, 2026
- CLUSTER reportMar 2, 2026
- CLUSTER reportFeb 25, 2026
- PRESS-RELEASE reportMar 2, 2026
- CLUSTER reportFeb 25, 2026